ClinicalTrials.gg
RecruitingNCT07409922Updated Aug 5, 2026

Study of Single and Multiple Ascending Doses of KR23343 in Healthy Adult Participants

A Phase 1 interventional study of KR23343 and Matching Placebo in Healthy, sponsored by Jiangxi Kvvit Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Jiangxi Kvvit Pharmaceutical Co., Ltd. (part of Qingfeng Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a Phase I, single-center trial to assess the safety, tolerability, PK and food effect of KR23343 in healthy volunteers. The study will be conducted in 3 sequential stages:

Stage 1: Single-Ascending-Dose (SAD) study A randomized, double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability, and PK of single ascending doses of KR23343.

Stage 2: Food-Effect (FE) study An open-label, randomized, two-period, two-sequence crossover study to evaluate the effect of food on the PK of a single dose of KR23343.

Stage 3: Multiple-Ascending-Dose (MAD) study A randomized, double-blind, placebo-controlled, dose-escalation study to investigate the safety, tolerability, and PK of repeated once-daily administration of KR23343 for 10 days.

Read the detailed description

This first-in-human study will investigate the safety, tolerability, and pharmacokinetics (PK) of KR23343 following single and multiple ascending oral doses in healthy subjects, as well as assess the effect of food on the PK of KR23343. The results of this study will be used to select doses for subsequent studies in patients.

Primary objectives:

Stage 1: To assess the safety and tolerability of single ascending oral doses of KR23343 in healthy participants. Stage 3: To assess the safety and tolerability of multiple ascending oral doses of KR23343 in healthy participants.

Secondary objectives:

Stage 1: To assess the PK profile of KR23343 following single oral doses in healthy participants and evaluate the effect of KR23343 tablets on the corrected QT interval (QTcF) and other electrocardiogram (ECG) parameters. Stage 2: To assess the PK profile, safety and tolerability of a single dose of KR23343 following high-fat food intake relative to fasting conditions in healthy participants. Stage 3: To assess the PK profile of KR23343 after repeated oral doses in healthy participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Jiangxi Kvvit Pharmaceutical Co., Ltd. is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female participants aged 18 to 45 years, inclusive.
  2. (BMI) between 19 and 28 kg/m² (inclusive) and body weight ≥ 50 kg for males or ≥45 kg for females.
  3. All screening assessments (vital signs, physical examination, laboratory tests, ) must be within normal limits or deemed not by the investigator. One repeat assessment is permitted during the screening period to confirm eligibility.
  4. Participants must agree not to donate gametes (sperm or ova), must not be planning pregnancy, and must use a reliable method from the time of signing through 3 months following the last dose.
  5. Able to understand study requirements, provide written informed consent, and comply with all trial procedures per protocol.

Exclusion criteria

Exclusion Criteria:

  1. or allergic to KR23343.
  2. History of severe hypersensitivity reactions or multiple drug/food allergies
  3. Significant disease affecting the central nervous, cardiovascular, gastrointestinal, respiratory, renal, hematologic, metabolic, or musculoskeletal systems, or any condition considered by the Investigator to make the participant unsuitable for the trial.
  4. Any surgical or medical condition that may significantly affect drug absorption, distribution, metabolism, or excretion, or compromise participant safety, including but not limited to urinary tract obstruction, dysuria, gastroenteritis, peptic ulcer disease, or history of gastrointestinal bleeding.
  5. History of psychiatric disorders or cerebral dysfunction; suicidal ideation identified by the Columbia-Suicide Severity Rating Scale (C-SSRS) or investigator judgment; or history of self-harm behavior.
  6. Abnormal screening investigations meeting any of the following criteria: a) Hepatic dysfunction: or AST>1.5x (ULN), or total >1.3x ULN; b) \<80 mL/min (calculated by Cockcroft-Gault formula: CrCl = [(140 - age) × weight (kg)] / [0.814 × Scr (μmol/L)], multiplied by 0.85 for females); c) Vital signs outside specified ranges (heart rate \<50 or >100 bpm, systolic blood pressure \<90 or ≥140 mmHg, diastolic blood pressure \<60 or ≥90 mmHg, tympanic temperature \<35.7 or >38.0°C); d) -F interval ≥450 ms (males) or ≥470 ms (females), or other abnormalities; e) Any other screening abnormality deemed clinically significant by the investigator.
  7. Blood loss or donation ≥400 mL within 3 months prior to screening, or planned donation during the study.
  8. Use of any medication within 2 weeks (or 5 half-lives, whichever is longer) prior to screening or during the study, including prescription drugs, over-the-counter medications, Chinese herbal products, dietary supplements, vaccines, or any drug known to induce or inhibit hepatic metabolizing enzymes (e.g., , CYP3A5).
  9. Participation in a clinical trial involving products, vaccines, or devices within 3 months prior to screening, or within 5 half-lives of the last dose, whichever is longer.
  10. History of drug abuse or illicit drug use within 6 months prior to screening, or positive urine drug screen.
  11. Hazardous alcohol consumption ( >14 units/week; 1 unit = 360 mL beer, 25 mL 40% spirits, or 100 mL wine) within 6 months prior to screening, inability to abstain from screening through end-of-study, or positive alcohol breath test.
  12. Smoking >10 cigarettes per day within the 3 months prior to screening, or inability to abstain from smoking and nicotine products during the trial.
  13. Regular consumption of >8 cups/day (1 cup = 250 mL) of grapefruit juice, tea, coffee, or caffeinated beverages within the 3 months prior to screening, or inability to abstain during the trial.
  14. Positive serology for surface antigen (HBsAg), virus (HCV) antibody, Treponema pallidum antibody, or (HIV) antibody.
  15. Pregnancy, lactation, or clinically significant abnormal pregnancy test as judged by the investigator.
  16. Specific dietary restrictions or inability to adhere to the standardized diet during their CPU stay.
  17. Difficult venous access, history of vasovagal syncope (needle or blood phobia), or inability to tolerate venipuncture.
  18. Any condition or circumstance that, in the opinion of the Investigator, would make the participant unsuitable for the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Stage 1 Dose 1

    Stage 1 Dose 1 Single dose of 10 mg

    Drug: KR23343

  • Experimental
    Stage 1 Dose 2

    Stage 1 Dose 1 Single dose of 20 mg

    Drug: KR23343

  • Experimental
    Stage 1 Dose 3

    Stage 1 Dose 3 Single dose of 30 mg

    Drug: KR23343

  • Experimental
    Stage 1 Dose 4

    Stage 1 Dose 4 Single dose of 45 mg

    Drug: KR23343

  • Experimental
    Stage 1 Dose 5

    Stage 1 Dose 5 Single dose of 60 mg

    Drug: KR23343

  • Placebo comparator
    Stage 1 placebo

    Stage 1 placebo Single dose of placebo

    Drug: Matching Placebo

  • Experimental
    Stage 2 30 mg KR23343 Fed state

    KR23343 oral single dose with food

    Drug: KR23343

  • Experimental
    Stage 2 30 mg KR23343 Fasted state

    KR23343 oral single dose without food

    Drug: KR23343

  • Experimental
    Stage 3 Dose 1

    KR23343 oral daily dose for 10 days (Dose 20mg QD )

    Drug: KR23343

  • Experimental
    Stage 3 Dose 2

    KR23343 oral daily dose for 10 days (Dose 30mg QD )

    Drug: KR23343

  • Experimental
    Stage 3 Dose 3

    KR23343 oral daily dose for 10 days (Dose 45 mg QD )

    Drug: KR23343

  • Placebo comparator
    Stage 3 placebo

    Placebo oral daily dose for 10 days

    Drug: Matching Placebo

Interventions

  • DrugKR23343

    Participants will receive oral administrations of KR23343

  • DrugMatching Placebo

    Participants will receive placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events, Serious Adverse Event(s) (SAEs), And Adverse Events Leading To Study Discontinuation

    The number of participants with recorded treatment emergent adverse events, SAEs, and adverse events leading to study discontinuation following single and multiple doses of KR23343

    Time frame: 7 days in stage 1;21 days in stage 2; 16 days in stage 3.

  2. Number of participants with abnormal laboratory test results, abnormal vital signs, abnormal physical examination findings, and abnormal ECG parameters

    Hematology, urinalysis, clinical chemistry, coagulation studies, vital signs (tympanic temperature, pulse, sitting blood pressure), and 12-lead ECGs (including heart rate, PR, RR, QRS, QT intervals, and QTcF) will be assessed at screening, pre-dose,and at post-dose timepoints as specified in the study

    Time frame: 7 days in stage 1;21 days in stage 2; 16 days in stage 3.

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) of Stage 1

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of KR23343.

    Time frame: Day 1 up to 144 hours post-dose

  2. Area Under the Plasma Concentration Versus Time Curve (AUC) of Stage 1

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of KR23343.

    Time frame: Day 1 up to 144 hours post-dose

  3. Time to Cmax (Tmax) of Stage 1

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of KR23343.

    Time frame: Day 1 up to 144 hours post-dose

  4. Elimination Half-life(t1/2)of Stage1

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of KR23343.

    Time frame: Day 1 up to 144 hours post-dose

  5. Peak Plasma Concentration (Cmax) of Stage 2

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of KR23343 under fasting and fed condition.

    Time frame: Day 1 up to 144 hours post-dose

  6. Area Under the Plasma Concentration Versus Time Curve (AUC) of Stage 2

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of KR23343 under fasting and fed condition.

    Time frame: Day 1 up to 144 hours post-dose

  7. Time to Cmax (Tmax) of Stage 2

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of KR23343 under fasting and fed condition.

    Time frame: Day 1 up to 144 hours post-dose

  8. Elimination Half-life(t1/2)of Stage 2

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of KR23343 under fasting and fed condition.

    Time frame: Day 1 up to 144 hours post-dose

  9. Peak Plasma Concentration (Cmax) of Stage 3

    Blood samples were collected at specified time points to perform pharmacokinetic (PK) analysis of multiple-dose KR23343

    Time frame: Day 1 up to 144 hours post-last dose

  10. Blood and Plasma Area Under the Concentration-Time Profile From Time 0 to Time Tau (AUCtau) of Stage 3

    Blood samples were collected at specified time points to perform pharmacokinetic (PK) analysis of multiple-dose KR23343

    Time frame: Day 1 up to 144 hours post-last dose

  11. Time to Cmax (Tmax) of Stage 3

    Blood samples were collected at specified time points to perform pharmacokinetic (PK) analysis of multiple-dose KR23343

    Time frame: Day 1 up to 144 hours post-last dose

  12. Evaluation of the effect of time-matched plasma concentrations of KR23343 on electrocardiogram (ECG) parameters and the QTc interval, including concentration-QTc analysis for Stage 1

    The placebo-corrected baseline-adjusted QTc (ΔΔQTc) was derived as the time-matched difference between the Day 1 change-from-baseline QTc values observed with KR23343 and those observed with placebo, calculated separately for each post-dose assessment timepoint.

    Time frame: Day 1 up to 144 hours post-dose

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 13, 2026
StartActual
Feb 5, 2026
Primary completionEst.
Nov 20, 2026
CompletionEst.
Nov 20, 2026
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07409922
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Feb 5, 2026
Primary completion
Nov 20, 2026 (estimated)
Completion
Nov 20, 2026 (estimated)
Last update
Aug 5, 2026

Study contacts

Jing Zhang
Contact
zhangj_fudan@163.com
021-52887926
Peimin Yu
Contact
021-52888158

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion